Compare CAPL & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CAPL | AMPH |
|---|---|---|
| Founded | 1992 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 889.1M | 885.4M |
| IPO Year | 2012 | 2005 |
| Metric | CAPL | AMPH |
|---|---|---|
| Price | $22.76 | $23.59 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $28.38 |
| AVG Volume (30 Days) | 41.9K | ★ 326.4K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 9.96% | N/A |
| EPS Growth | ★ 96.15 | N/A |
| EPS | 0.78 | ★ 0.81 |
| Revenue | ★ $1,869,806,000.00 | $719,887,000.00 |
| Revenue This Year | N/A | $6.90 |
| Revenue Next Year | $2.80 | $4.64 |
| P/E Ratio | $29.74 | ★ $28.44 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $19.67 | $16.65 |
| 52 Week High | $24.63 | $29.52 |
| Indicator | CAPL | AMPH |
|---|---|---|
| Relative Strength Index (RSI) | 49.16 | 66.77 |
| Support Level | $22.37 | $18.36 |
| Resistance Level | $24.63 | $24.35 |
| Average True Range (ATR) | 0.49 | 0.69 |
| MACD | -0.09 | 0.06 |
| Stochastic Oscillator | 24.70 | 81.95 |
CrossAmerica Partners LP is engaged in the wholesale distribution of motor fuel and the ownership and leasing of real estate used in the retail distribution of motor fuel. The company operates through two business segments, namely Wholesale and Retail. The Wholesale segment is a key revenue driver and includes the wholesale distribution of motor fuel to lessee dealers, independent dealers, commission agents, DMS, Circle K, and through company-operated retail sites. The Retail segment includes the sale of convenience merchandise items, the retail sale of motor fuel at company-operated retail sites, and the retail sale of motor fuel at retail sites operated by commission agents.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.